The purpose of this study is to evaluate efficacy and feasibility of adaptive radiotherapy according to tumor volume change (TVC) in early stage non-small cell lung cancer (NSCLC) using stereotactic body radiotherapy (SBRT). Twenty-two lesions previously treated with SBRT were selected. SBRT was usually performed with a total dose of 48 Gy or 60 Gy in four fractions with an interval of three to four days between treatments. For evaluation of TVC, gross tumor volume (GTV) was contoured on each cone-beam computed tomography (CBCT) image used for image guidance. Intensity modulated radiotherapy (IMRT) planning was performed in the first CBCT (CBCT1) using a baseline plan. For ART planning (ART), re-optimization was performed at 2 nd , 3 rd , and 4 th CBCTs (CBCT2, CBCT3, and CBCT4) using the same angle and constraint used for the baseline plan. The ART plan was compared with the non-ART plan, which generated copying of the baseline plan to other CBCTs. Average GTV volume was 10.7 cc. Average TVC was -1.5%, 7.3%, and -25.1% in CBCT2, CBCT3, and CBCT4 and the TVC after CBCT3 was significant (p＜0.05). However, the nine lesions were increased GTV in CBCT2. In the ART plan, V20 Gy, D1500 cc, and D1000 cc of lung were significantly decreased (p＜0.05), and V30 Gy and V32 Gy of the chest wall were also decreased (p＜0.05). While D min of planning target volume (PTV) decreased by 8.3% in the non-ART plan of CBCT2 compared with the baseline plan in lesions with increased tumor size (p=0.021), PTV coverage was not compromised in the ART plan. Based on this result, use of the ART plan may improve target coverage and OAR saving. Thus ART using CBCT should be considered in early stage NSCLC with SBRT.
Introduction
The standard treatment for early stage non-small cell lung cancer (NSCLC) is lobar resection, however a portion of patients are medically inoperable. Stereotactic body radiotherapy (SBRT), with a 3-year local control rate of 80∼90%, has been suggested as an alternative treatment option in these patients. 1, 2) In recent series, the results of SBRT were comparable or better than those for sublobar resection. [3] [4] [5] Several studies reported that higher biologically equivalent dose was related to improved local control and survival. 6, 7) However, large fraction size may increase the toxicities of organs at risk (OARs), including the lung, 8) chest wall 9, 10) and large bronchus. 11) Therefore, a smaller margin around the tumor is warranted in order to reduce radiation-induced normal tissue toxicities.
In the course of SBRT, there are several uncertainties related to tumor geometry, motion and volume, hindering the reduction of the margin. For adjustment of tumor geometry and motion, an on board imager such as cone-beam computed tomography (CBCT) and 4-dimensional computed tomography are widely used. Tumor volume change (TVC) can be easily observed in CBCT images using image guidance. TVC during the course of radiotherapy in NSCLC is well established in the case of conventional radiotherapy. 12, 13) TVC has also been reported even in SBRT despite its short overall treatment time. [14] [15] [16] [17] [18] 
Materials and Methods

Patients
A total of 36 lesions in 34 patients treated with SBRT for early-stage NSCLC at Yeungnam University Medical Center were reviewed retrospectively. SBRT was usually performed with a total dose of 48 Gy to 60 Gy in four fractions with an interval of three to four days between treatments using Novalis TX (Varian Medical Systems Inc., Palo Alto, CA). CBCT was performed in each fraction for image guidance. Of these patients, those with an ill-defined tumor margin were excluded in order to reduce error in the analysis of the TVC. Thus, 22 lesions in 20 patients were selected for this study.
Contouring
Gross tumor volume (GTV) and OARs were delineated in four CBCT datasets per patient (CBCT1, CBCT2, CBCT3, and CBCT4, corresponding to first through fourth treatment) by an experienced radiation oncologist using Eclipse (Varian Medical Systems Inc., Palo Alto, CA). To reduce error, tumor was delineated under the same window width/level of -90/900 Hounsefield units. Planning target volume (PTV) was generated by addition of 3-mm margin to GTV. The chest wall and whole lung were delineated as OARs. The chest wall was delineated up to 1 cm superiorly and inferiorly from PTV.
Planning procedure
The rigid image registration was performed between CBCT1 and other CBCTs. A baseline intensity modulated radiotherapy (IMRT) plan was generated on CBCT1 with an analytic anisotropic algorithm. Dose prescription was normalized for 90% of PTV to receive 100% of a prescribed dose. Maximal point dose must be in PTV and not over 125% of a prescription dose. For generation of a non-adaptive plan, the baseline plan including MLC leaf motion, beam parameters and angles was copied to CBCT2, CBCT3, and CBCT4 with adjustment of the isocenter, and the dose distribution was calculated without optimization. 
Dosimetric parameters and statistical analysis
Differences in the GTV between CBCT1 and other CBCT datasets were evaluated using both absolute and relative values. ). All patients were treated in four fractions with the following fraction sizes: 12 Gy in 11 patients, 13 Gy in 1, and 15 Gy in 12.
Tumor volume change
Changes of GTV are shown in Fig. 2 and Table 1. TVC was not statistically significant in all patients in CBCT2, but the GTV was increased in nine lesions. However, the GTV was significantly smaller in CBCT3 (92.7%) and CBCT4 (83.9%) than in CBCT1. Fig. 3 shows the gradual decrease of the GTV volume. 
Dosimetric comparison between non-ART versus ART
Dosimetric parameters are summarized in Table 2 . In the adaptive plan, there was a significant decrease in V20 Gy, D1500 cc, and D1000 cc of the lung, and V30 Gy and V32 Gy of the chest wall (p＜0.05). In peripheral tumors within 2 cm from the chest wall, V30 Gy and V32 Gy decreased by approximately 1.0 and 1.6 cc.
The coverage of PTV in CBCT2 was evaluated in the lesions that grew in CBCT2 (Table 3 and Fig. 5 ). Dmin was decreased by approximately 8.3% in non-ART. However PTV coverage was not compromised compared with the initial plan in the ART plan.
Discussion
Our study showed a significant change of tumor volume during the course of SBRT. The tumor volume was usually reduced except on the second treatment day. Despite a short treatment time, tumor regression during the course of SBRT has been reported. Yi et al. 18) reported that mean overall reduction was 21.1% during the course of SBRT with three to five fractions over two weeks. In addition, increase of the tumor volume at a certain time during the course of SBRT has been reported, whereas the tumor volume decreased in the conventional fractionation. 12, 13, [20] [21] [22] In our study nine lesions showed increased tumor volume at the second CBCT. Saito et al. 16) re- ported that the median tumor size was larger on the third treatment day compared to the first day with a median enlargement of 1.53 cm 3 during the course of SBRT of 48 Gy over four consecutive days. Gunter at al, 15) who studied TVC in 25 NSCLC with SBRT during the course of SBRT of 50 Gy divided into 5 fractions, reported that the GTV of 4 lesions had increased on the second treatment day. Tatekawa at al. 17) reported that volume expansion of over 10% was observed in 32% of patients on the third treatment day with 48 Gy for T1 tumors and 52 Gy for T2 tumors divided into 4 fractions over a two-week schedule. This temporary increase of the tumor volume could be explained by the fact that tumor volume may increase due to edema induced by large fraction size and subsequently decreased by early response.
The factor of GTV enlargement was studied. Our study showed that tumor size of the 15 Gy fraction size group with larger fraction size was more frequently increased compared with the ＜15 Gy group. The pain flare phenomenon in radiotherapy might explain this finding. The pain flare may be caused tumoral edema 23) and the incidence increased in spine SBRT with higher fraction size. 24) Our study showed that PTV coverage was decreased with increasing tumor size. Dmin was significantly reduced by approximately 8.3%. Shirata et al. 25) reported that minimal dose could affect local control in stage I NSCLC with SBRT. The 3-year local control rates were 100% in patients with Dmin for PTV of more than 89.88% versus 79.2% in those with dose for PTV less than 89.88%. However, the impact of the temporary increase of tumor volume on local control is uncertain.
When tumor size decreases, ART could be useful for decreasing the dose of OARs. Chest wall toxicity was significantly related to dose-volume parameters 9, 10) and in our study, V30 Gy and V32 Gy of the chest wall were significantly reduced in the adaptive plan. Bhatt et al. 14) reported that the doses of the chest wall and left ventricle were reduced in adaptive plans compared with initial plans. And, in our study, V20 Gy, D1500 cc, and D1000 cc of the lung, which are related to lung toxicity, were also significantly decreased in the adaptive plan. Barriger et al. 26) reported that radiation pneumonitis of grade 3 or more was observed in 4.3% of patients with V20 Gy of less than 4% compared with 16.4% of patients with V20 Gy of ＞4% (p=0.03).
There are several concerns regarding use of the adaptive plan using CBCT. The first is dosimetric feasibility of planning using CBCT images. Yoo et al. 27) reported that dosimetric error of the CBCT-based plan was only up to 3% compared to the CT-based plan with an inhomogenous phantom. Yang et al. 28) also concluded that CBCT-based dose calculation was acceptable in prostate cases. Therefore, adaptive planning using CBCT appears to be acceptable. The second is the contouring error. Altojai et al. 29) reported an interobserver reliability coefficient of 0.97 in CBCT contouring for early-stage NSCLC and concluded that CBCT imaging is an effective tool for target volume delineation. Finally, adaptive target delineation based on tumor regression could cause under-dose in the microscopic disease. However, Gukenberger et al. 30) reported that ART did not compromise dose coverage in the microscopic disease.
Conclusion
Our 
